Notably, we observed simultaneous anti-cancer effects with improvements in liver pathology and insulin sensitivity in our HFD/obesity-driven TRAMP model following Camkk2 ablation (Figure 3). This evidence concerns the gene CAMKK2 and obesity disorder.